Core Wealth Advisors LLC Takes Position in Merck & Co., Inc. $MRK

Core Wealth Advisors LLC bought a new stake in shares of Merck & Co., Inc. (NYSE:MRK) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 4,798 shares of the company’s stock, valued at approximately $505,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. D.A. Davidson & CO. raised its holdings in Merck & Co., Inc. by 4.4% during the 4th quarter. D.A. Davidson & CO. now owns 576,959 shares of the company’s stock valued at $60,731,000 after buying an additional 24,576 shares during the period. Farther Finance Advisors LLC raised its holdings in Merck & Co., Inc. by 48.9% during the 4th quarter. Farther Finance Advisors LLC now owns 97,818 shares of the company’s stock valued at $10,296,000 after buying an additional 32,114 shares during the period. Coldstream Capital Management Inc. raised its holdings in Merck & Co., Inc. by 12.7% during the 3rd quarter. Coldstream Capital Management Inc. now owns 123,366 shares of the company’s stock valued at $10,364,000 after buying an additional 13,940 shares during the period. NEOS Investment Management LLC raised its holdings in Merck & Co., Inc. by 39.9% during the 3rd quarter. NEOS Investment Management LLC now owns 347,684 shares of the company’s stock valued at $29,181,000 after buying an additional 99,074 shares during the period. Finally, Campbell Capital Management Inc. purchased a new stake in Merck & Co., Inc. during the 3rd quarter valued at $1,866,000. 76.07% of the stock is currently owned by institutional investors.

Merck & Co., Inc. Price Performance

MRK opened at $118.49 on Friday. Merck & Co., Inc. has a 12-month low of $75.40 and a 12-month high of $125.14. The company has a current ratio of 1.30, a quick ratio of 1.06 and a debt-to-equity ratio of 1.02. The business’s fifty day simple moving average is $116.39 and its 200-day simple moving average is $111.46. The company has a market capitalization of $292.66 billion, a price-to-earnings ratio of 33.38, a PEG ratio of 2.67 and a beta of 0.18.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.19. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The business had revenue of $16.29 billion for the quarter, compared to the consensus estimate of $15.85 billion. During the same quarter in the prior year, the company earned $2.22 EPS. The business’s revenue was up 4.9% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. On average, equities research analysts anticipate that Merck & Co., Inc. will post 5.16 earnings per share for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, July 8th. Stockholders of record on Monday, June 15th will be given a dividend of $0.85 per share. The ex-dividend date of this dividend is Monday, June 15th. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.9%. Merck & Co., Inc.’s dividend payout ratio is presently 95.77%.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: The FDA granted Breakthrough Therapy designation to calderasib (MK-1084) with Keytruda in a lung cancer indication, a sign the program may move faster and expand Merck’s oncology growth prospects. Article Title
• Positive Sentiment: Analyst coverage and recent articles highlighted Merck’s newer drugs, pipeline assets, and M&A options as potential offsets to looming Keytruda patent expiration, reinforcing the bull case for long-term growth. Article Title
• Positive Sentiment: Merck has also been drawing investor attention as a trending stock and has outperformed the S&P 500 over the past year, suggesting market confidence remains relatively strong. Article Title
• Neutral Sentiment: Merck will participate in the Jefferies Global Healthcare Conference, which could provide an update on strategy but is not itself a major business catalyst. Article Title
• Neutral Sentiment: Shareholders backed board nominees, pay, and auditor ratification at the annual meeting, which reduces governance uncertainty but is unlikely to move the stock much. Article Title
• Negative Sentiment: The main longer-term concern remains Keytruda’s eventual loss of exclusivity, which could pressure Merck’s biggest revenue driver if replacement products do not scale quickly enough. Article Title

Wall Street Analyst Weigh In

Several research firms recently weighed in on MRK. Citigroup began coverage on Merck & Co., Inc. in a report on Wednesday, May 6th. They set a “neutral” rating and a $125.00 price target on the stock. Cantor Fitzgerald increased their price target on Merck & Co., Inc. from $116.00 to $120.00 and gave the company a “neutral” rating in a report on Wednesday, February 4th. JPMorgan Chase & Co. increased their price target on Merck & Co., Inc. from $125.00 to $135.00 and gave the company an “overweight” rating in a report on Monday, April 6th. Wall Street Zen lowered Merck & Co., Inc. from a “buy” rating to a “hold” rating in a report on Saturday, May 16th. Finally, Deutsche Bank Aktiengesellschaft upgraded Merck & Co., Inc. from a “hold” rating to a “buy” rating and set a $150.00 price target on the stock in a report on Friday, February 13th. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and seven have given a Hold rating to the stock. According to data from MarketBeat, Merck & Co., Inc. has a consensus rating of “Moderate Buy” and an average target price of $128.18.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.